Candel Therapeutics Inc. (CADL)
NASDAQ: CADLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CADL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $395.37M
- EPS (TTM)
- -$1.53
- Dividend yield
- None
- 52-week range
- 4.35 – 14.00
- Day range
- 4.90 – 5.31
- Volume / Avg
- 1.72M / 1.26M
- Beta
- —
- Shares outstanding
- 78.45M
52-week range
CADL stock today
Candel Therapeutics (CADL) closed at $5.04 on Nov 20, down 1.75% (-$0.09), versus the S&P 500's 3.70% decline. At this level, CADL sits near the bottom of its 52-week range of $4.35 to $14.00: 64.0% below the high, set on Aug 27, 2026 and 15.9% above the low. CADL is down 10.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.8%.
Candel Therapeutics has posted a net loss over the last twelve months (EPS of -$1.53), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Candel Therapeutics
Company profileCandel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
- Headquarters
- Needham, MA
- Employees
- 55
- IPO year
- 2021
- Website
- candeltx.com
Financial highlights
Full financialsCandel Therapeutics reported a net loss of $38.2 million, compared with a loss of $55.2 million a year earlier. Diluted earnings per share came in at -$0.72.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $125.00K | $125.00K |
| Growth | — | — | — | 0.00% | 0.00% |
| Net income | $-38.18M | $-55.18M | $-37.94M | $-18.79M | $-36.12M |
| EPS (diluted) | $-0.72 | $-1.74 | $-1.31 | $-0.65 | $-1.91 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$17.67+250.60%
- Strong buy 0
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.28 vs $-0.30
- Surprise
- +6.67%
CADL news
All CADL news- Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower - Hagens BermanPR Newswire
- Why is Candel Therapeutics stock collapsing today?Investing.com
- Candel Therapeutics stock plummets 35% on prostate cancer BLA delayInvesting.com
- Candel Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Plans Middle of 2027 BLA Submission for AglatimageneNasdaq
- Candel Therapeutics GAAP EPS of -$0.28 beats by $0.07Seeking Alpha
- Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswire
- Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage PortfolioGlobeNewswire
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Candel Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TVGNTevogen Inc. | 5.90 | -6.35% | $405.20M | vs CADL |
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs CADL |
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs CADL |
| IRLAIRulya Therapeutics Inc. | 39.88 | -0.15% | $432.36M | vs CADL |
| ALECAlector Inc. | 2.34 | +1.52% | $347.63M | vs CADL |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs CADL |
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs CADL |
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs CADL |
Indexes, lists and sector
Candel Therapeutics stock FAQ
What is Candel Therapeutics's stock price today?
CADL last traded at $5.04 as of Nov 20, 4:00 PM EST, down 1.75% on the day. Prices are delayed at least 15 minutes.
Who is Candel Therapeutics's CEO?
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. is the chief executive officer of Candel Therapeutics Inc., which has about 55 employees.
What is the CADL 52-week high?
The 52-week high for CADL is $14.00 and the 52-week low is $4.35. The stock is currently 64.0% below its high.